Livestreamed from Washington DC, this year’s presentations from the American College of Cardiology annual meeting included discussion and latest data on the therapeutic potential of omega-3 fatty acids in atherosclerotic cardiovascular disease (ASCVD), results from the TRANSLATE-TIMI 70 and APOLLO trials, and latest insights on nutritional approaches to reduction of CV risk.
Reportage by Jenny Bryan
Read the reports:
- Is serum EPA level key to omega-3 benefit in ASCVD?
- Vupanorsen data from Translate-TIMI 70
- Phase 1 APOLLO explores siRNA for Lp(a) reduction
- SuperWIN: targeting nutrition for CV risk improvement
- PROMINENT trial update for pemafibrate in type 2 diabetes
- Therapeutic lifestyle modification to lower TGs
